SCHEMBL5776920

SCHEMBL5776920

Cc1ccc(S(=O)(=O)N2CCN(c3ccc(C(F)(F)F)cc3Br)CC2)cc1CC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.51
MAPK1 P28482 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MEN1 O00255 1/20 0.46
RECQL P46063 1/20 0.46
KMT2A Q03164 1/20 0.46
RAB9A P51151 1/20 0.46
PTPN11 Q06124 3/20 0.45
GAA P10253 1/20 0.44
HTT P42858 2/20 0.43
TSHR P16473 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
APOBEC3A P31941 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
HSD11B1 P28845 1/20 0.42
MAPT P10636 1/20 0.41
CNR1 P21554 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5748224 0.85 HTT (0.52) MEN1KMT2APTPN11GAAHTT
SCHEMBL6346332 0.82 ALDH1A1 (0.52) LMNAMEN1KMT2APTPN11GAA
SCHEMBL5487074 0.81 KDM4E (0.59) LMNASMN1; SMN2MEN1KMT2AGAA
SCHEMBL5770474 0.81 KDM4E (0.63) LMNAMAPK1SMN1; SMN2MEN1KMT2A
SCHEMBL5745816 0.81 LMNA (0.45) LMNAMEN1KMT2APTPN11GAA
SCHEMBL4212900 0.80 ALDH1A1 (0.57) GAACNR1PTGDR2
SCHEMBL5747530 0.79 LMNA (0.52) LMNAMAPK1SMN1; SMN2KMT2APTPN11
SCHEMBL13805196 0.79 CNR1 (0.67) SMN1; SMN2KMT2AGAACNR1
SCHEMBL6348135 0.78 KDM4E (0.66) LMNASMN1; SMN2MEN1KMT2AGAA
SCHEMBL6349175 0.78 HSD11B1 (0.61) MEN1KMT2APTPN11HSD11B1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD LMNA 3289/4885MAPK1 3430/4885SMN1; SMN2 2173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.